Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Medeon Biodesign (6499) operate in?
Medeon Biodesign belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is Medeon Biodesign (6499) current stock price?
As of the latest data, Medeon Biodesign stock price is NT$66.80, with a previous close of NT$61.20. Medeon Biodesign gained NT$5.60 in the last trading session, representing a 9.15% increase.
What is Medeon Biodesign (6499) current market capitalization?
Medeon Biodesign market cap is approximately 6.48 billion.
What is Medeon Biodesign (6499) Earnings Per Share (EPS)?
The trailing EPS is -NT$7.24, and the forward EPS is NT$2.95.
Does Medeon Biodesign (6499) pay dividends?
No. Medeon Biodesign does not pay a dividend.
What is Medeon Biodesign (6499) beta (volatility) score?
Medeon Biodesign has a beta of 0.600, indicating lower volatility than the overall market.
